Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer
About this trial
This is an interventional treatment trial for Non Small Cell Lung Cancer
Eligibility Criteria
Inclusion Criteria Histologically or cytologically proven IIIB and IV NSCLC. No symptomatic uncontrolled brain metastasis Not suitable for platinum containing regimens if chemo-naive Performance status less than or equal to 2 on the Eastern Cooperative Oncology Group (ECOG) Scale. Creatinine Clearance (CrCl) greater than or equal to 45 milliliters per min (mL/min) Exclusion Criteria Prior radiation to greater than 25% of bone marrow Inability to interrupt Aspirin at doses of greater than 1.3 grams/day or non-steroidal anti-inflammatory agents for a 5-day period. Presence of clinically relevant third-space fluid collections not controllable. Significant cardiac disease
Sites / Locations
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Pemetrexed - Before Protocol Amendment
Pemetrexed - After Protocol Amendment